Clinical Edge Journal Scan

Anti-TNF-α therapy reduces incidence of nailfold capillaroscopic abnormalities in PsA


 

Key clinical point: A 12-month anti-tumor necrosis factor-alpha (anti-TNF-α) regimen improved nailfold capillaroscopic abnormalities in patients with psoriatic arthritis (PsA), highlighting the usefulness of nailfold videocapillaroscopy in the evaluation of disease severity and in monitoring the efficacy of biologic treatment.

Major finding: After 12 months of initiating anti-TNF-α therapy, the proportion of patients with PsA showing structural integrity increased from 29.4% to 67.6% and those of patients with low capillaroscopic density and avascular areas decreased from 30.3% to 15.2% and 39.4% to 24.2%, respectively. The use of anti-TNF-α therapy was positively associated with a decrease in angiogenesis ( P = .0003) and in the number of giant capillaries ( P = .007) and elongated capillaries ( P = .0003).

Study details: Findings are from a retrospective observational study including patients with PsA (n=34) and those with rheumatoid arthritis (n=34) who received anti-TNF-α therapy and control individuals (n=24).

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Anghel D et al. Nailfold videocapillaroscopy in patients with rheumatoid arthritis and psoriatic arthropathy on ANTI-TNF-ALPHA therapy. Diagnostics (Basel). 2023;13(12):2079 (Jun 15). Doi: 10.3390/diagnostics13122079.

Recommended Reading

For psoriasis, review finds several biosimilars as safe and effective as biologics
MDedge Rheumatology
Oral IL-23 receptor antagonist for psoriasis promising: Phase 2b study
MDedge Rheumatology
Keep depression, anxiety screening top of mind in patients with psoriatic disease
MDedge Rheumatology
Remote teams offer chance to improve difficult-to-treat PsA
MDedge Rheumatology
Humira biosimilars: Five things to know
MDedge Rheumatology
Beta-defensin-2 may serve as a predictive biomarker for clinical response to secukinumab in PsA
MDedge Rheumatology
Predictors of treatment response in PsA patients initiating a first TNFi
MDedge Rheumatology
Real-world study confirms clinical efficacy of ixekizumab in PsA
MDedge Rheumatology
Apremilast offers a safe long-term oral treatment option for psoriatic arthritis
MDedge Rheumatology
Improvement in patient-reported outcomes comparable with ustekinumab and TNFi in PsA
MDedge Rheumatology